These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38980837)

  • 61. Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study.
    de Mello VD; Lindström J; Eriksson J; Ilanne-Parikka P; Keinänen-Kiukaanniemi S; Sundvall J; Laakso M; Tuomilehto J; Uusitupa M
    Diabetes Care; 2012 Feb; 35(2):211-7. PubMed ID: 22210578
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population.
    Badings EA; Dyal L; Schoterman L; Lok DJ; Stoel I; Gerding MN; Gerstein HC; Tijssen JG
    J Diabetes; 2011 Sep; 3(3):232-7. PubMed ID: 21631894
    [TBL] [Abstract][Full Text] [Related]  

  • 63. People with impaired glucose tolerance and impaired fasting glucose are similarly susceptible to cardiovascular disease: a study in first-degree relatives of type 2 diabetic patients.
    Amini M; Horri N; Zare M; Haghighi S; Hosseini SM; Aminorroaya A; Hovsepian S
    Ann Nutr Metab; 2010; 56(4):267-72. PubMed ID: 20413967
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study.
    Hanefeld M; Koehler C; Fuecker K; Henkel E; Schaper F; Temelkova-Kurktschiev T;
    Diabetes Care; 2003 Mar; 26(3):868-74. PubMed ID: 12610051
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of cardiovascular disease and risk factors in the Chinese population with impaired glucose regulation: the 2007-2008 China national diabetes and metabolic disorders study.
    Yang Z; Xing X; Xiao J; Lu J; Weng J; Jia W; Ji L; Shan Z; Liu J; Tian H; Ji Q; Zhu D; Ge J; Lin L; Chen L; Guo X; Zhao Z; Li Q; Zhou Z; Shan G; Yang W;
    Exp Clin Endocrinol Diabetes; 2013 Jun; 121(6):372-4. PubMed ID: 23616189
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictive risk factors for deterioration from normoglycemic state to type 2 diabetes mellitus or impaired glucose tolerance in a Tunisian urban population.
    Chihaoui M; Kanoun F; Ben Rehaiem B; Ben Brahim S; Ftouhi B; Mekaouar A; Fekih M; Mbazâd A; Zouari B; Ben Khalifa F
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):487-95. PubMed ID: 11547223
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Appearance of undiagnosed diabetes mellitus in the population of professionally active people in the urban areas].
    Wierusz-Wysocka B; Zozulińska D; Knast B; Pisarczyk-Wiza D
    Pol Arch Med Wewn; 2001 Sep; 106(3):815-21. PubMed ID: 11928591
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impaired glucose regulation in adults in Jamaica: who should have the oral glucose tolerance test?
    Sargeant LA; Boyne MS; Bennett FI; Forrester TE; Cooper RS; Wilks RJ
    Rev Panam Salud Publica; 2004 Jul; 16(1):35-42. PubMed ID: 15333264
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM.
    Motala AA; Omar MA; Gouws E
    Diabetes Care; 1997 Jul; 20(7):1101-7. PubMed ID: 9203444
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hypertriglyceridemia in different degrees of glucose intolerance in a Finnish population-based study.
    Salomaa VV; Tuomilehto J; Jauhiainen M; Korhonen HJ; Stengård J; Uusitupa M; Pitkanen M; Penttila I
    Diabetes Care; 1992 May; 15(5):657-65. PubMed ID: 1516486
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study.
    Kabootari M; Asgari S; Ghavam SM; Abdi H; Azizi F; Hadaegh F
    J Transl Med; 2021 Jun; 19(1):277. PubMed ID: 34193200
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial.
    Ali MK; Singh K; Kondal D; Devarajan R; Patel SA; Menon VU; Varthakavi PK; Vishwanathan V; Dharmalingam M; Bantwal G; Sahay RK; Masood MQ; Khadgawat R; Desai A; Prabhakaran D; Narayan KMV; Tandon N
    PLoS Med; 2024 Jun; 21(6):e1004335. PubMed ID: 38829880
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Premature death and risk of cardiovascular disease in young-onset diabetes: a 23-year follow-up of the Da Qing Diabetes Study.
    Hui Y; Wang J; An Y; Gong Q; Li H; Zhang B; Shuai Y; Chen Y; Hu Y; Li G
    Endocrine; 2019 Jul; 65(1):46-52. PubMed ID: 31001730
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.
    Zhang L; Zhang Y; Shen S; Wang X; Dong L; Li Q; Ren W; Li Y; Bai J; Gong Q; Kuang H; Qi L; Lu Q; Cheng W; Liu Y; Yan S; Wu D; Fang H; Hou F; Wang Y; Yang Z; Lian X; Du J; Sun N; Ji L; Li G;
    Lancet Diabetes Endocrinol; 2023 Aug; 11(8):567-577. PubMed ID: 37414069
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study.
    Henninger J; Hammarstedt A; Rawshani A; Eliasson B
    BMC Endocr Disord; 2015 Sep; 15():51. PubMed ID: 26407933
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Ipsen EØ; Madsen KS; Chi Y; Pedersen-Bjergaard U; Richter B; Metzendorf MI; Hemmingsen B
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013516. PubMed ID: 33210751
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Plasma glucose concentration 60 min post oral glucose load and risk of type 2 diabetes and cardiovascular disease: Pathophysiological implications.
    Abbasi F; Tern PJ; Reaven GM
    Diab Vasc Dis Res; 2019 Jul; 16(4):337-343. PubMed ID: 30755013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.